返回 
加入收藏
马昔腾坦相关不良事件信号的挖掘与分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 马昔腾坦相关不良事件信号的挖掘与分析 |
| TITLE： | Mining and analysis of adverse drug event signals related to macitentan |
| 摘要： | 目的 挖掘肺动脉高压（PAH）治疗药物马昔腾坦的相关不良事件（ADE）信号，为临床安全用药提供参考。方法收集美国FDA不良事件报告系统（FAERS）数据库中2013年第4季度至2023年第3季度的马昔腾坦相关ADE报告，采用比例失衡法中的报告比值比（ROR）法、英国药品和保健品管理局的综合标准法（简称“MHRA法”）进行数据挖掘，根据《国际医学用语词典》26.0版中的系统器官分类（SOC）和首选术语（PT）对ADE名称进行规范化编码，并进行事件发生时间（TTO）分析和威布尔分布形状参数（WSP）检验。结果共提取到以马昔腾坦为首要怀疑药物的ADE报告26079份，涉及患者以女性居多（73.25%），且集中于18～65岁（42.39%），主要上报国家为美国（84.42%），严重治疗结果以住院或住院时间延长（59.82%）最为常见。挖掘出马昔腾坦ADE阳性信号269个；甲状腺功能减退症，血肌酐升高、血尿素升高等肾损伤相关ADE，以及精神淡漠、绝望感等精神障碍相关ADE未被其药品说明书收录。TTO分析结果提示，大部分马昔腾坦ADE阳性信号发生在初始治疗后的0～30d（492份，21.52%）和＞360d（411份，17.98%）；WSP检验结果显示，报告数排前20位的ADE阳性信号大多符合早期失败型曲线特征。结论临床在应用马昔腾坦治疗PAH时，除药品说明书中提及的不良反应外，还应重点关注甲状腺功能障碍、肾功能障碍、精神障碍等相关ADE。 |
| ABSTRACT： | OBJECTIVE To mine adverse drug event （ADE） signals related to the pulmonary arterial hypertension （PAH） therapeutic drug macitentan， and to provide reference for safe clinical medication. METHODS Macitentan-related ADE reports were collected from the US FDA Adverse Event Reporting System （FAERS） database from the fourth quarter of 2013 to the third quarter of 2023. Data mining was conducted by using the reporting odds ratio （ROR） method and the comprehensive standard method established by the UK Medicines and Healthcare Products Regulatory Agency （referred to as “MHRA method”） under the proportional imbalance approach. According to the systemic organ class （SOC） and preferred term （PT） stated in 26.0 edition of Medical Dictionary of Regulatory Activities， standardized coding of ADE names was performed， followed by the analysis of time to onset （TTO） and the Weibull shape parameter （WSP） test. RESULTS Overall， a total of 26 079 ADE reports were identified with macitentan as the primary suspect drug. These reports predominantly involved female patients （73.25%） and were concentrated in the age range of 18 to 65 years （42.39%）. The majority of reports originated from the US （84.42%）， with hospitalization or prolonged hospital stays （59.82%） being the most common in severe treatment outcome. A total of 269 ADE positive signals related to macitentan were identified. Among these， hypothyroidism， ADE related to renal injury such as the increase of serum creatinine and blood urea nitrogen， and ADE related to psychiatric disorders like apathy and despair were not included in the drug label. TTO analysis indicated that the majority of macitentan-related ADE signals occurred between 0-30 days after initial treatment （492 reports， 21.52%） and over 360 days （411 reports， 17.98%）. The results of WSP test showed that most of the top 20 reported ADE signals conformed to the characteristics of an early failure curve. CONCLUSIONS When clinically using macitentan in patients with PAH， attention should be given not only to the adverse reactions mentioned on the drug label but also to thyroid dysfunction， kidney dysfunction and mental disorder-related ADEs. |
| 期刊： | 2024年第35卷第13期 |
| 作者： | 吴镇湖；陈鑫遥；陈耀鑫；许银姬 |
| AUTHORS： | WU Zhenhu，CHEN Xinyao，CHEN Yaoxin，XU Yinji |
| 关键字： | 马昔腾坦；肺动脉高压；药品不良事件；信号挖掘；比例失衡法；合理用药 |
| KEYWORDS： | macitentan； pulmonary arterial hypertension； |
| 阅读数： | 11 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
